Becton, Dickinson and Company BDX

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 70 years of manufacturing in Sandy, Utah, a key part of the company's U.S. manufacturing network and a critical source of the medical technologies healthcare providers and patients depend on for daily care worldwide.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Waters (NYSE:WAT) President and Chief Executive Officer Udit Batra said the company’s second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses. Speaking at a JPMo

The global smoke evacuation systems market is forecast to grow from USD 0.20 billion in 2025 to USD 0.30 billion by 2031, at a 7.5% CAGR. Growth is driven by rising minimally invasive, electrosurgical and laparoscopic procedures, stricter surgical smoke safety guidance, and demand for better operating room air quality. Smoke evacuation pencils and wands lead the product segment, while laparoscopic surgery holds the largest application share. The US is expected to record North America’s fastest g

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice president and chief information and digital officer, effective September 30.

Becton Dickinson (NYSE:BDX) reached an SEC cease and desist settlement over past Alaris infusion pump risk disclosures, including a civil penalty and creation of a Fair Fund for investors. Subsidiary C.R. Bard recently faced a plaintiff verdict in Bard PowerPort litigation, with thousands of related product liability cases still pending. The Alaris disclosure settlement and Bard PowerPort verdict both tie into a wider pattern of legal and compliance pressures our research tracks. We have...

Life sciences solutions and products provider Thermo Fisher Scientific (NYSE:TMO)’s shares have done well in September and are up by more than 8% since the 10th. On the 15th, Cramer discussed the strength in the shares in a conversation with his co-host David Faber amidst the turmoil in the AI sector on the back of […]

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacy operations.

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09. This cash dividend is payable on 2026-09-30. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.

Becton, Dickinson and Company has notably outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects.